Today: 16 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Tesla Stock Price Today: Why TSLA Is Slipping as FSD Probe Overshadows Europe Approval Hopes

Tesla Stock Price Today: Why TSLA Is Slipping as FSD Probe Overshadows Europe Approval Hopes

Tesla shares lost 1.4% to $375.11 late Friday morning in New York, deepening a slide sparked by tougher U.S. regulatory scrutiny over its self-driving tech. The pressure lingered even as the National Highway Traffic Safety Administration turned down a broad recall request involving roughly 2.26 million vehicles. The stock had already tumbled 3.2% Thursday after the government escalated a separate probe into Full Self-Driving.
20 March 2026
·
Intel Stock Price Today: INTC Slips as Broader Chip Weakness Tests the Turnaround

Intel Stock Price Today: INTC Slips as Broader Chip Weakness Tests the Turnaround

Intel slipped 1% early Friday, trimming some of Thursday’s rally, as chip stocks came under pressure alongside a weaker market. By 10:06 a.m. EDT, shares traded at $45.71, down 1.0%. Nvidia slid 1.3%, AMD dropped 1.5%, Broadcom lost 0.9%. Qualcomm bucked the trend, up 0.8%. The Nasdaq started the day off 0.46% as investors adjusted rate-cut expectations amid Middle East unrest.
20 March 2026
··
Rivian Stock Price Today: RIVN Slides as Wall Street Weighs Uber’s $1.25 Billion Robotaxi Bet

Rivian Stock Price Today: RIVN Slides as Wall Street Weighs Uber’s $1.25 Billion Robotaxi Bet

Rivian Automotive, Inc. shares skidded 6% to $15.21 as of 9:45 a.m. EDT Friday, unwinding gains from a $16.12 close the day before. This came right after Uber’s $1.25 billion robotaxi deal was unveiled—the news boosted Rivian on Thursday, but investors quickly circled back to expenses tied to pushing the company’s autonomous ambitions.
20 March 2026
···
FTC Sends More Than $58 Million to Invitation Homes Renters, Credit Repair Victims

FTC Sends More Than $58 Million to Invitation Homes Renters, Credit Repair Victims

The Federal Trade Commission is distributing over $58.1 million to close to 887,000 people via two refund efforts—one tied to a March 17 payout for victims of a credit repair scam, the other a March 11 refund aimed at Invitation Homes tenants. The bulk of the money, more than $47.2 million, reaches 444,131 renters. Another $10.9 million-plus is going out to 443,048 consumers who paid Financial Education Services.
20 March 2026
·
Miss This IRS Tax Refund Step and You Could Wait 10 Weeks for Your Money

Miss This IRS Tax Refund Step and You Could Wait 10 Weeks for Your Money

U.S. taxpayers who don’t provide direct deposit information—or whose banks bounce back a refund—could be waiting weeks for their IRS refunds under updated payment rules. In a March 9 letter, House Ways and Means Committee Democrats said the IRS had already issued 530,000 CP53E notices and was preparing to send another 300,000 that week, putting this season’s total above 830,000.
20 March 2026
Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk slipped 1.5% to 237.90 Danish crowns in Copenhagen on Thursday, despite the FDA signing off on a higher-dose Wegovy injection. The stock remained in the red after Eli Lilly unveiled new obesity drug results, and as Reuters flagged that semaglutide patent expiry in India could clear the way for lower-cost generics of the compound found in both Wegovy and Ozempic.
20 March 2026
··
1 … 170 171 172 173 174 … 882

Stock Market Today

  • AstraZeneca (LSE:AZN) Seen Undervalued Against Cash Flow Estimates
    July 16, 2026, 11:08 AM EDT. AstraZeneca (LSE:AZN) looks undervalued on discounted cash flow, even with its $60.4 billion in revenue and a wide drug lineup. Analysts point to a solid oncology and specialty medicines pipeline, with newer assets like Zegfrovy, Enhertu, and TRUQAP expected to add to future sales. Risks are there-heavy R&D spend, high debt, and blockbuster drug pressures. Still, some say the current share price isn't pricing in the cash flow outlook, and value-focused investors may see an opportunity around long-term cash returns.
Go toTop